Citius Pharmaceuticals, Inc. (CTXR) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on September 15, 2023, regarding an event that occurred on September 12, 2023. The Company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol "CTXR".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter rather than financial performance.
Material Changes
The primary material event is a notification from Nasdaq Stock Market LLC stating that the Company's common stock bid price closed below the minimum $1.00 per share requirement for 30 consecutive business days. This constitutes a failure to satisfy Nasdaq Listing Rule 5550(a)(2), known as the "Bid Price Rule."
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending on March 11, 2024, to regain compliance.
- Regaining Compliance: Compliance can be achieved if the bid price closes at $1.00 or more for 10 consecutive business days before the deadline.
- Secondary Options: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period. This requires meeting other listing standards (excluding the bid price) and potentially effecting a reverse stock split.
- Delisting Risk: Failure to regain compliance by the required deadlines may result in delisting. The Company retains the right to appeal a delisting determination to a Nasdaq hearings panel.
- Current Status: The notice has no immediate effect on the listing; the stock continues to trade on Nasdaq. Management is evaluating options to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current trading price of CTXR to assess the gap from the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split to cure the deficiency.
- Review the Company's market value of publicly held shares to ensure eligibility for a second compliance period if needed.
- Track the 10 consecutive business day closing price requirement leading up to the March 11, 2024 deadline.